Literature DB >> 16334122

Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy.

Vesa Kärjä1, Sirpa Aaltomaa, Pertti Lipponen, Taina Isotalo, Martti Talja, Risto Mokka.   

Abstract

AIM: The aim of the study was to evaluate the prognostic significance of tumour-infiltrating lymphocytes (TILs) in local prostate cancer (PC).
MATERIALS AND METHODS: TILs were counted and routine histological variables were assessed from radical prostatectomy specimens in 188 cases of PC. Immunohistochemical (IHC) characterisation of the lymphocytes was done by using CD4 and CD8 antibodies for detection of T lymphocytes and CD20 antibody for B lymphocytes in tissue microarray construction. The results of the lymphocyte analyses were compared to other prognostic factors and PSA recurrence-free survival (RFS).
RESULTS: Strong expression of TILs, CD4, CD8 and CD20 lymphocytes were seen in 28%, 33%, 35% and 15% of the cases, respectively. CD4 and CD8, as well as CD4 and CD20, lymphocytes were correlated to each other (p < 0.0001), but not to clinical or histopathological parameters. Weak expression of TILs was correlated with intracapsular carcinoma (p = 0.004), while perineural invasion (p = 0.017) and capsular invasion (p < 0.0001) were related to strong expression of TILs. Shortened PSA RFS was associated with strong expression of TILs (p = 0.005). In Cox regression analysis, independent predictors of shortened PSA RFS were strong expression of TILs (p = 0.012) and high Gleason score (p < 0.001).
CONCLUSION: TILs are an independent predictor of short PSA RFS in patients with local PC treated by radical prostatectomy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16334122

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  57 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

Review 2.  The inflammatory microenvironment and microbiome in prostate cancer development.

Authors:  Karen S Sfanos; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Nat Rev Urol       Date:  2017-10-31       Impact factor: 14.432

3.  Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact.

Authors:  Joo Yeon Kim; Woo Gyeong Kim; Chae Hwa Kwon; Do Youn Park
Journal:  Gastric Cancer       Date:  2019-05-31       Impact factor: 7.370

Review 4.  Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity.

Authors:  Caroline Jochems; Jeffrey Schlom
Journal:  Exp Biol Med (Maywood)       Date:  2011-04-12

Review 5.  Prostate cancer and inflammation: the evidence.

Authors:  Karen S Sfanos; Angelo M De Marzo
Journal:  Histopathology       Date:  2012-01       Impact factor: 5.087

6.  Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer.

Authors:  Lisa K Spary; Josephine Salimu; Jason P Webber; Aled Clayton; Malcolm D Mason; Zsuzsanna Tabi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

Review 7.  Mechanisms of cancer dissemination along nerves.

Authors:  Moran Amit; Shorook Na'ara; Ziv Gil
Journal:  Nat Rev Cancer       Date:  2016-05-06       Impact factor: 60.716

Review 8.  MSMB variation and prostate cancer risk: clues towards a possible fungal etiology.

Authors:  Siobhan Sutcliffe; Angelo M De Marzo; Karen S Sfanos; Martin Laurence
Journal:  Prostate       Date:  2014-01-24       Impact factor: 4.104

9.  Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival.

Authors:  Christina Hägglöf; Peter Hammarsten; Andreas Josefsson; Pär Stattin; Janna Paulsson; Anders Bergh; Arne Ostman
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

Review 10.  Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.

Authors:  Amos Kirilovsky; Florence Marliot; Carine El Sissy; Nacilla Haicheur; Jérôme Galon; Franck Pagès
Journal:  Int Immunol       Date:  2016-04-27       Impact factor: 4.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.